These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 26116494

  • 1. Relating Spontaneously Reported Extrapyramidal Adverse Events to Movement Disorder Rating Scales.
    Widschwendter CG, Karayal ON, Kolluri S, Vanderburg D, Kemmler G, Fleischhacker WW.
    Int J Neuropsychopharmacol; 2015 Jun 26; 18(12):. PubMed ID: 26116494
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
    Bartkó G, Trixler M, Bitter I, Degrell I, Füredi J, Faludi G, Ziprasidonra Váltást Vizsgáló Munkacsoport.
    Neuropsychopharmacol Hung; 2006 Dec 26; 8(4):201-9. PubMed ID: 17211055
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L, Meng X, Hochfeld M, Stahl SM.
    Hum Psychopharmacol; 2012 Jan 26; 27(1):24-32. PubMed ID: 22161738
    [Abstract] [Full Text] [Related]

  • 5. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
    Miceli JJ, Tensfeldt TG, Shiovitz T, Anziano RJ, O'Gorman C, Harrigan RH.
    Clin Ther; 2010 Mar 26; 32(3):472-91. PubMed ID: 20399985
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.
    Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T.
    Schizophr Res; 2003 Jun 01; 61(2-3):123-36. PubMed ID: 12729864
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study.
    Brook S, Walden J, Benattia I, Siu CO, Romano SJ.
    Psychopharmacology (Berl); 2005 Apr 01; 178(4):514-23. PubMed ID: 15650846
    [Abstract] [Full Text] [Related]

  • 10. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia.
    Hirsch SR, Kissling W, Bäuml J, Power A, O'Connor R.
    J Clin Psychiatry; 2002 Jun 01; 63(6):516-23. PubMed ID: 12088164
    [Abstract] [Full Text] [Related]

  • 11. Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol.
    Corripio I, Catafau AM, Perez V, Puigdemont D, Mena E, Aguilar Y, Carrió I, Alvarez E.
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan 01; 29(1):91-6. PubMed ID: 15610950
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
    Tran PV, Dellva MA, Tollefson GD, Beasley CM, Potvin JH, Kiesler GM.
    J Clin Psychiatry; 1997 May 01; 58(5):205-11. PubMed ID: 9184614
    [Abstract] [Full Text] [Related]

  • 16. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Möller HJ, Riedel M, Jäger M, Wickelmaier F, Maier W, Kühn KU, Buchkremer G, Heuser I, Klosterkötter J, Gastpar M, Braus DF, Schlösser R, Schneider F, Ohmann C, Riesbeck M, Gaebel W.
    Int J Neuropsychopharmacol; 2008 Nov 01; 11(7):985-97. PubMed ID: 18466670
    [Abstract] [Full Text] [Related]

  • 17. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
    Shim JC, Shin JG, Kelly DL, Jung DU, Seo YS, Liu KH, Shon JH, Conley RR.
    Am J Psychiatry; 2007 Sep 01; 164(9):1404-10. PubMed ID: 17728426
    [Abstract] [Full Text] [Related]

  • 18. Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled Study.
    Schennach R, Riedel M, Spellmann I, Musil R, Obermeier M, Jäger M, Bottlender R, Schmauss M, Laux G, Möller HJ.
    Pharmacopsychiatry; 2019 Jul 01; 52(4):180-185. PubMed ID: 30235496
    [Abstract] [Full Text] [Related]

  • 19. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial.
    Kennedy JS, Jeste D, Kaiser CJ, Golshan S, Maguire GA, Tollefson G, Sanger T, Bymaster FP, Kinon BJ, Dossenbach M, Gilmore JA, Breier A.
    Int J Geriatr Psychiatry; 2003 Nov 01; 18(11):1013-20. PubMed ID: 14618553
    [Abstract] [Full Text] [Related]

  • 20. Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America.
    Costa e Silva JA, Alvarez N, Mazzotti G, Gattaz WF, Ospina J, Larach V, Starkstein S, Oliva D, Cousins L, Tohen M, Taylor CC, Wang J, Tran PV.
    J Clin Psychopharmacol; 2001 Aug 01; 21(4):375-81. PubMed ID: 11476121
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.